RMTC Adopts Therapeutic Medication Guidelines for Race Horses

Newsdate: Sat, 23 Mar 2013 - 11:37 am
Location: BALTIMORE, Maryland

At its March 19 meeting in Baltimore, Maryland, the Racing Medication and Testing Consortium (RMTC) board of directors adopted recommendations for thresholds and withdrawal times for four therapeutic medications identified by the Association of Racing Commissioners International (RCI). The recommendations were for procaine penicillin, lidocaine, detomidine and xylazine.

Safer medication use in race horses

Safer medication use in race horses

The RMTC board of directors has adopted recommendations for thresholds and withdrawal times for four therapeutic medications identified by the RCI for use in race horses, including procaine penicillin, lidocaine, detomidine and xylazine.

While some of the recommendations were termed interim recommendations, the adoption of these thresholds and withdrawal times will enable the RCI to provide its members with a complete list for the 24 therapeutic medications identified by the RCI, RMTC and the American Association of Equine Practitioners.

“The RMTC’s approval of these last few thresholds and withdrawal times from the set of 24 therapeutic substances identified by the industry represents a significant investment of resources by the RMTC and its stakeholders,” said RMTC Chairman Dr. Robert Lewis. “These guidelines will pave the way for uniform adoption of medication regulations across the country.”

The completion of this list also coincides with the recent effort toward medication and testing uniformity undertaken in the Mid-Atlantic and Northeast states.

“The adoption of these final thresholds is a key step that will enable RCI to enact the Controlled Therapeutic Substances List, which will then enable the participating states to begin the adoption and implementation process,” stated RMTC Vice Chairman and Thoroughbred Horsemen’s Association Chairman Alan Foreman, Esq.

In addition to the four therapeutic substances identified, the RMTC board also approved secondary thresholds for two non-steroidal anti-inflammatories (NSAIDs) – phenylbutazone and flunixin meglumine. A secondary threshold is the permissible level for a second medication where there are two medications of the same type (here phenylbutazone, flunixin or ketoprofen). The primary threshold no longer applies to the second NSAID found in a sample. Instead, a lower secondary threshold applies to the second medication.

The secondary thresholds were adopted in response to concerns over administration of multiple NSAIDs within 48 hours of racing – a practice known as “stacking.”

“The administration of multiple NSAIDs is a welfare and safety concern for our equine and human athletes,” said Dr. Rick Arthur, RMTC Scientific Advisory Committee Chair and California’s Equine Medical Director. “The adoption of secondary thresholds will avoid the administration of phenylbutazone and flunixin in combination within 48 hours of racing.”

About the Author

Flossie Sellers

Author picture

As an animal lover since childhood, Flossie was delighted when Mark, the CEO and developer of EquiMed asked her to join his team of contributors.

She enrolled in My Horse University at Michigan State and completed a number of courses in everything related to horse health, nutrition, diseases and conditions, medications, hoof and dental care, barn safety, and first aid.

Staying up-to-date on the latest developments in horse care and equine health is now a habit, and she enjoys sharing a wealth of information with horse owners everywhere.

Subscribe